CEO & President, Founder
Canary's lead product candidate is a drug candidate to treat rheumatoid arthritis that includes a combination of microRNA targets.
Canary has already developed and registered a molecular POC dx platform that can detect genomic material with high sensitivity and specificity.
President and CEO, Canary Cure Therapeutics
Chief Strategy Officer, Co-Founder
Senior Scientific Advisor, Gene Therapy and Rare Diseases
Senior Scientific & Medical advisor, Molecular Metabolism
Senior Clinical Development advisor, Obesity & Metabolic Disorder
View DetailsSenior Clinical Development advisor, Obesity & Metabolic Disorder
Senior Scientific Advisor, Obesity & Metabolic Disorders
Legal and Licensing Advisor
Senior Medical Advisor, Neurological Disorders, Parkinson’s Disease
View DetailsSenior Medical Advisor, Neurological Disorders, Parkinson’s Disease
Senior Scientific and Medical advisor , Rare Neurological Disease
Senior Scientific and Medical advisor , Rare Neurological Disease
MD Senior Medical Advisor